In laboratory tests, researchers at Tel Aviv University and MIT have used gene therapy to prevent metastasis – the spread of breast cancer to other parts of the body. 80% of women with metastatic cancer die from the disease within … Continue reading →

The UN has prioritized fighting antibiotic resistance. Meanwhile, the European Commission has granted 2.3 million Euros to Israeli biotech MeMed to help develop its fast blood test that distinguishes between bacterial and viral infections – and thus significantly reduces the … Continue reading →

MotionCure from Israel’s Sidis Labs can provide relief from motion sickness within minutes.  MotionCure’s combination of a neck collar and a travel pillow transmits customized pulses to the median nerve at the back of neck. These counter negative signals from … Continue reading →

The first patient with Sickle Cell Disease (SCD) has received a transplant of CordIn from Israeli biotech Gamida Cell.  CordIn is an alternative for patients awaiting a suitable match for bone marrow transplants.  Trials of CordIn are planned for patients … Continue reading →

Quark is a US company with its R&D in Israel.  The US Patent and Trademark Office has granted Quark a key patent for its ocular neuro-protectant QPI-1007, covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy (NAION). … Continue reading →

Israel’s Check-cap, developer of the world’s first ingestible colon X-ray capsule, has announced three key news items.  It is partnering with GE Healthcare to develop high-volume manufacturing. It also received $1.2 million from the Israeli government and $5.9 million from … Continue reading →

Israel’s Teva has launched in the US the generic equivalent to Gleevec (imatinib mesylate) for the treatment of leukemia and other cancer-related diseases. Also, Europe has approved Teva’s CINQAERO (reslizumab) – the first intravenous anti-IL-5 biologic therapy for severe eosinophilic … Continue reading →

Israel’s InSeal Medical has received CE Mark approval for its InClosure VCD (Vascular Closure Device), designed to close large bore arterial punctures. These could be emergencies such as abdominal aortic aneurysms or in procedures such as heart valve replacements. http://www.prnewswire.com/news-releases/inseal-medical-ltd-announces-ce-mark-approval-for-the-inclosure-large-bore-vascular-closure-device-589461411.html

The US FDA has approved the Hyper-CL contact lens for the treatment of corneal edema developed by Israel’s EyeYon Medical. The product is already approved for marketing in Europe. About two million people develop corneal edema annually. http://www.eye-yon.com/press-eyeyon-medical-announces-receiving-fda-510-k-clearance/ https://www.youtube.com/watch?v=rknqew9dhxk  (See … Continue reading →